Problems with Olanzapine Acute Dystonia Caused by H 2 Blocker Post-transplant Diabetes and Immunosuppressive Drugs Hepatitis Associated with Hydroxyurea Ototoxicity and Cisplatin
Restricted accessOtherFirst published online October, 1999
Problems with Olanzapine Acute Dystonia Caused by H 2 Blocker Post-transplant Diabetes and Immunosuppressive Drugs Hepatitis Associated with Hydroxyurea Ototoxicity and Cisplatin
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (1-800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
ShusterJ.ISMP Adverse Drug Reactions. Hosp Pharm.1999; 34: 820–3.
2.
LeeJ.W., CrismonM.L., DorsonP.G.Seizure associated with olanzapine. Ann Pharmacother.1999; 33: 554–6.
3.
MarcusE., VassA., ZislinJ.Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother.1999; 33: 697–700.
